Skip to main content

Table 4 1-, 2-, 3-year Survival

From: A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma

Survival

Cohort 1 (N = 30)

Cohort 2 (N = 15)

1-year

18 (60%)

8 (53%)

2-year

14 (46.7%)

6 (40%)

3-year

9 (30%)

4 (26.7%)

Back to article page